Cassava Sciences Reports Q3 2025 Financials and Advances Simufilam
Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cassava Sciences, Inc. is a biotechnology company specializing in the development of novel treatments for central nervous system disorders, including Tuberous Sclerosis Complex-related epilepsy, with its proprietary investigational drug, simufilam.
The company recently reported its financial results for the third quarter of 2025, highlighting a significant reduction in net loss compared to the previous year and a strong cash position expected to support operations into 2027. Cassava is advancing simufilam towards a clinical study for TSC-related epilepsy, anticipated to begin in the first half of 2026.
Key financial metrics from the report include a net loss of $10.8 million, or $0.22 per share, a marked improvement from the $27.9 million loss in the same period of 2024. The company ended the quarter with $106.1 million in cash and cash equivalents, a decrease from $128.6 million at the end of 2024. Research and development expenses saw a significant decrease due to the completion of the Alzheimer’s disease program.
Strategically, Cassava has strengthened its board with the appointment of Dawn C. Bir and is preparing for a proof-of-concept study for simufilam in TSC-related epilepsy. Positive preclinical results have been reported, supporting simufilam’s potential as a first-in-class treatment.
Looking ahead, Cassava Sciences is focused on advancing its clinical initiatives and maintaining its financial health, with an optimistic outlook on the potential of simufilam in treating TSC-related epilepsy and other central nervous system disorders.
